Pfizer turns back Mylan’s patent challenge to Sutent

Eric Palmer

execs can sigh with relief now that a federal court has backed the company's patents on kidney cancer drug . The med has become increasingly important to Pfizer as sales of off- drugs have faded, and so it was alarming to the U.S. drugmaker when generics maker Mylan challenged the in 2010 and filed to make its own copy.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS